Whole Genome Amplification (WGA) offers vast opportunities in personalized medicine, cancer research, and reproductive health ...
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO and MENLO ...
SAN DIEGO/MENLO PARK - Illumina, Inc. (NASDAQ:ILMN) and genomics company MyOme announced Thursday a collaboration agreement and strategic investment to advance clinical applications of whole-genome ...
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood ...
Illumina exhibits better profitability ratios than many of its peers, which indicates that the company could continue to invest in its operations. In Q3 2025, ILMN raised its EPS to $4.65-$4.75, ...
“Illumina’s…presentations and product descriptions revealed a workflow that infringed on the ‘607, ‘138, ‘505, and ‘487 patents, 10x Genomics and Prognosys Biosciences argued.” On October 21, 10x ...
A pair of presentations at this year’s annual meeting of the American Society of Human Genetics highlighted some of the latest capabilities from sequencing giant Illumina. At the meeting, the company ...
SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback